Suzhou Zelgen Biopharmaceuticals Co., Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 282.1 million compared to CNY 197.89 million a year ago. Revenue was CNY 282.1 million compared to CNY 197.89 million a year ago.

Net loss was CNY 202.09 million compared to CNY 363.75 million a year ago. Basic loss per share from continuing operations was CNY 0.8 compared to CNY 1.52 a year ago. Diluted loss per share from continuing operations was CNY 0.8 compared to CNY 1.52 a year ago.